MMV & PARTNERS @ ICTMM 2016

International Congress for Tropical Medicine and Malaria
Brisbane Convention & Exhibition Centre

→ Malaria Drugs and Drug Resistance
→ MMV-DSM265
→ DNDi-MMV Special Symposium: Open Source Drug Discovery
→ MMV Symposium: From Fast Killing to Blocking the Life Cycle: New Potential Candidate Drugs for Malaria
→ MMV Translational Symposium
→ Poster Session

Defeating Malaria Together
Concurrent Session 2A

Great Hall
Monday 19 Sept
1.00 pm to 3.00 pm

**Malaria Drugs and Drug Resistance**

1233 Drug discovery to control and eradicate malaria
Jeremy Burrows, MMV, Switzerland (20)

560 Identification of novel new permeation pathway inhibitors in the blood stage of *Plasmodium falciparum*
Paul Gilson, The Burnet Institute, Australia (15)

570 Determining antimalarial efficacy in the first 24 hours after treatment
David Khoury, The University of New South Wales, Australia (15)

102 Malaria treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women
Ritah Mutagonda, Muhimbili University of Health and Allied Sciences, Tanzania (15)

9 Comparison of methemoglobin level between children and adults after treatment with primaquine
Ayodhia Pitaloka Pasaribu, University of Sumatera Utara, Indonesia (15)

Concurrent Session 4I

Great Hall
P4
Tuesday 20 Sept
10.00 am to 12.00 pm

**MMV-DSM265**

1152 Getting it together: the elements that went into the selection of the clinical candidate DSM265
Susan Charman, Monash University, Australia (15)

1203 An integrated phase I/Ib study to investigate the safety, tolerability and pharmacokinetic profile of DSM265 as well as its antimalarial activity in induced blood stage *Plasmodium falciparum* infection
James McCarthy, Queensland Institute of Medical Research, Australia (20)

1138 Assessing the prophylactic activity of a single dose of DSM265 in a controlled human malarial infection challenge by direct venous inoculation of *P. falciparum* sporozoites (PFSPZ)
Benjamin Mordmueller, University of Tübingen, Germany (15)

1167 Efficacy, safety, tolerability and pharmacokinetics of single doses of DSM265 in patients with acute, uncomplicated *P. falciparum* or *vivax* malaria mono-infection. Results from a phase IIa proof-of-concept study in Iquitos, Peru
Thomas Rueckle, MMV, Switzerland (15)
Concurrent Session 6I:
DNDi-MMV Special Symposium: Open Source Drug Discovery
Tuesday, 20 September

Concurrent Session 5I:
MMV Symposium: From Fast Killing to Blocking the Life Cycle: New Potential Candidate Drugs for Malaria
Tuesday, 20 September
**Concurrent Session 6I**

**DNDi-MMV Special Symposium: Open Source Drug Discovery**

**Chairs:**
- Robert Don, DNDi, Switzerland
- Matt Todd, University of Sydney, Australia

**1234 Opening up drug discovery**
- Jeremy Burrows, MMV, Switzerland

**452 Open innovation in neglected disease research**
- Robert Don

**462 The open source malaria consortium**
- Matt Todd

**Crowdsourcing new antimicrobials – the community for open antimicrobial drug discovery**
- Mark Blaskovich, CO-ADD, Australia

---

**Concurrent Session 5I**

**MMV Symposium: From Fast Killing to Blocking the Life Cycle: New Potential Candidate Drugs for Malaria**

**Chair:**
- Jeremy Burrows, MMV, Switzerland

**Co-chair:**
- Susan Charman, Monash University, Australia

**30 Novel oxaborole antimalarial candidate drug**
- Phil Rosenthal, University of California San Francisco, USA

**1222 Ongoing development of next-generation differentiated antimalarial drugs from phenotypic screens**
- John Haselden, GSK, Spain

**455 Next generation PI4K inhibitors that impact the entire parasite lifecycle**
- Kelly Chibale, H3D, University of Cape Town, South Africa

**458 Novel antimalarials from diversity oriented synthesis**
- Marshall Morningstar, Broad Institute, USA
Concurrent Session 9G:
MMV Translational Symposium
Wednesday, 21 September
**MMV Translational Symposium**

1. **Setting the scene**
   - **Joerg Moehrle**, MMV, Switzerland (5)

2. **Human Blood Stage Malaria Challenge Model**
   - **James McCarthy**, Queensland Institute of Medical Research, Australia (20)

3. **Modelling human data to improve clinical trial design**
   - **Joel Tarning**, University of Oxford, WWARN, Thailand (2)

4. **How CHMI can inform the development of 048 a PI4 kinase inhibitor**
   - **TBA**

5. **DHODH inhibitor, DSM265 for malaria**
   - **Joerg Moehrle**, MMV, Switzerland (20)

---

**Poster Session**

**First Poster Session**

- **Monday 19 Sept**
  - 9.00 am to 17.00 pm

189 **Pyronaridine (pyr) pharmacokinetics. Differences between healthy subjects and malaria-infected adults**
   - **Amal Ayyoub**, Stephan Duparc, Isabelle Borghini-Fuhrer, Jang-Sik Shin, Lawrence Fleckenstein

**Second Poster Session**

- **Tuesday 20 Sept**
  - 9.00 am to 17.00 pm

188 **Pyramax® (pyronaridine-artesunate) a decade of demonstrating efficacy and safety in patients**
   - **Stephan Duparc**, Isabelle Borghini-Fuhrer, Robert Miller, Sarah Arbe-Barnes, Adam Aspinall, Jangsik Shin, Lawrence Fleckenstein